FDA warns vendors of unapproved GLP‑1 products

The FDA has opened a new front in its long fight over copycat weight-loss drugs. On April 7, the agency published seven warning letters aimed at companies selling more than 20 GLP-1, dual GLP-1/GIP, and triple-agonist products online, often wrapped in the flimsy disclaimer that they were only for laboratory research. The targets included Prime Sciences, Lovega, Gram Peptides, FormPour, Guangzhou Huli Technology, Mile High Compounds, and PekCura Labs. The FDA’s point was simple: if you market these injectables with claims about weight loss, blood sugar, or heart health, they are drugs for human use, no matter what the label says (raps.org, fda.gov). That matters because these products were not just unapproved. The FDA said they were being sold in ways that made them especially risky. In its March 31 warning letter to PekCura Labs, the agency said injectable products can cause “serious and life-threatening conditions” because they bypass some of the body’s normal defenses. It also said PekCura’s site described “GLP-1-S” as producing substantial weight loss and affecting cardiovascular endpoints, which is exactly the kind of therapeutic pitch that turns a supposed research chemical into an unlawfully marketed drug (fda.gov). This is not a one-off cleanup. It is the latest step in a much broader crackdown that has been building for more than a year. In February 2024, the FDA warned US Chem Labs and Helix Chemical Supply for selling semaglutide and tirzepatide “for research purposes” while also making claims about weight loss, stroke risk, Alzheimer’s disease, and blood sugar control. By December 2024, the agency had expanded that approach to five more peptide sellers, saying that “research use only” language does not cancel out websites and social posts that plainly encourage human use (fda.gov, fda.gov, foley.com). The campaign then moved up the supply chain. In February 2026, FDA Commissioner Marty Makary said the agency intended to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs, warning that companies could not market compounded products as if they were the same as approved medicines. A month later, the FDA sent 30 warning letters to telehealth companies for implying that compounded semaglutide and tirzepatide were equivalent to Wegovy, Ozempic, Mounjaro, or Zepbound, or for disguising who actually made the drugs (fda.gov, fda.gov). What ties all of this together is the end of the shortage era. The FDA has already said its enforcement discretion for compounded tirzepatide under section 503A ended in early 2025, and for compounded semaglutide it ended later that spring, with limited extra time for some outsourcing facilities. That did not erase legitimate compounding in narrow cases. It did erase the convenient fiction that a booming gray market could keep acting like an emergency still existed. The agency is now treating online peptide sellers, telehealth marketers, and compounders as parts of the same problem: a demand explosion met by products the FDA has not reviewed for safety, effectiveness, or quality (fda.gov, fda.gov). The warning letters themselves are not product seizures. They are a formal notice and a countdown. Recipients are typically expected to respond within 15 business days and explain how they will fix the violations. The FDA has also made clear that if the answers are not good enough, it can move straight to stronger measures, including seizure or injunction. On April 7, it chose seven companies and more than 20 products to make that point again (fda.gov, raps.org).